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Guselkumab (an IL-23–specific mAb) demonstrates clinical
and molecular response in patients with moderate-to-severe
psoriasis
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and San Diego, Calif, Portland, Ore, St Louis, Mo, Spring House, Pa, and New York, NYBackground: IL-23 expression is increased in psoriatic lesions
and might regulate TH17 T-cell counts in patients with psoriasis.
Objectives: We sought to test a novel IL-23–specific therapeutic
agent for the treatment of psoriasis.
Methods: In this randomized, double-blind, placebo-controlled
study the safety, tolerability, and clinical response of
guselkumab, an anti–IL-23–specific mAb, were evaluated in
patients with moderate-to-severe plaque psoriasis. A total of
24 patients were randomized to receive a single dose of placebo
or 10, 30, 100, or 300 mg of guselkumab. Clinical response was
assessed by using the Psoriasis Area and Severity Index (PASI).
Additionally, histologic analysis and gene expression in skin
biopsy specimens from guselkumab-treated patients were
compared with those from placebo-treated patients.
Results: At week 12, 50% (10 mg), 60% (30 and 100 mg), and
100% (300 mg) of guselkumab-treated patients, respectively,
achieved a 75% improvement in PASI scores from baseline
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Open access under CC BY-NC-ND license.in PASI scores were generally maintained through week 24 in
all guselkumab-treated patients. The proportion of patients
experiencing an adverse event was comparable between the
combined guselkumab (13/20 [65.0%]) and placebo
(2/4 [50.0%]) groups through week 24. Analysis of lesional and
nonlesional skin biopsy specimens demonstrated decreases in
epidermal thickness and T-cell and dendritic cell expression in
guselkumab-treated patients compared with values seen in
placebo-treated patients. At week 12, significant reductions in
psoriasis gene expression and serum IL-17A levels were
observed in guselkumab-treated patients.
Conclusion: IL-23 inhibition with a single dose of guselkumab
results in clinical responses in patients with moderate-to-severe
psoriasis, suggesting that neutralization of IL-23 alone is a
promising therapy for psoriasis. (J Allergy Clin Immunol
2014;133:1032-40.)
Key words: Histology, IL-23, gene expression, guselkumab, psoria-
sis, Psoriasis Area and Severity Index, serum, skin, T cell, TH17
Psoriasis is the most common immune-mediated skin disor-
der.1,2 Psoriatic skin lesions contain increased infiltrates of T cells
(TH1, TH17, and TH22). Inflammatory CD11c
1 dendritic cells
(DCs) and macrophages in the skin become activated and release
IL-12 and IL-23, which stimulate cytokine production from T
cells. Epidermal T cells are responsible for secreting cytokines,
including IFN-g (TH1), IL-17A and IL-17F (TH17), IL-22
(TH22), and TNF-a.
3 The molecular disease profile of psoriasis,
as defined by mRNA transcripts, contains hundreds of activated
genes that can be linked to effects on individual or multiple
cytokines.4 IFN-g, IL-17A or IL-17F, and IL-22 have distinct
effects on epidermal keratinocytes, which have been implicated
as key regulators of psoriatic skin inflammation.3
IL-12 and IL-23 levels are increased in psoriatic lesions. It is
believed that IL-12 modulates the excess TH1 population,
whereas IL-23 is the major regulator of TH17 T cells. The role
of IL-12/TH1 T cells to sustain the psoriasis phenotype is
debated because other inflammatory diseases thought to be
TH1-dependent proved to be IL-23/TH17-mediated
5 and because
IL-17 antagonists can suppress the clinical, cellular, and molecu-
lar disease features of psoriasis.6 Conversely, the IL-23/TH17 axis
is hypothesized to be important in patients with psoriasis;
however, IL-17 can also be produced in skin lesions indepen-
dently of IL-23 by neutrophils and mast cells.7 Therefore,
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ascertained by means of selective antagonism of this cytokine.
IL-23 is a type 1 heterodimer comprised of p19 and p40
subunits that bind to the IL-23 receptor complex comprised of
IL-23 receptor (IL-23R) and IL-12 receptor b1 (IL-12Rb1).
Binding of p19 (IL-23R) and p40 (IL-12Rb1) to their respective
receptors activates the IL-23 signaling pathway in which IL-23R
associates with Janus kinase 2 and IL-12Rb1 binds to tyrosine
kinase 2 (Janus kinase protein).8 IL-23p19 and IL-12/23p40
mRNAs are strongly upregulated in human psoriatic lesions.9-11
The main cellular source of IL-23 in psoriatic lesions appears to
be myeloid DCs, which can be immature inflammatory cells or
mature populations (DC-lysosomal-associated membrane pro-
teins [LAMP]112,13 or CD8311).
Guselkumab (CNTO 1959; Janssen Research & Development,
LLC, Spring House, Pa) is an investigational human mAb
specifically directed against IL-23. Here the proof-of-concept
study of an anti–IL-23 mAb in patients with moderate-to-severe
plaque psoriasis is reported. The objectives of this double-blind,
placebo-controlled study were to assess the safety, tolerability,
and clinical response to guselkumab in patients with moderate-
to-severe plaque psoriasis. Histologic and gene expression
studies of skin biopsy specimens were included in this
study to evaluate which cellular and molecular disease
features might be selectively regulated by IL-23 in patients with
psoriasis.METHODS
This phase 1, first-in-human, randomized, double-blind, placebo-
controlled trial included 24 patients with moderate-to-severe plaque psoriasis
and was conducted at 5 sites in the United States. Patient eligibility criteria
are reported in the Methods section in this article’s Online Repository at
www.jacionline.org. All patients provided written informed consent, and
institutional review boards/ethics committees approved the protocol.Study design
At baseline, 24 patients were randomly assigned to receive subcutaneous
injections of 10 mg (n5 5), 30 mg (n5 5), 100 mg (n5 5), or 300 mg (n5 5)
of guselkumab or placebo (n 5 4).Study assessments
Safety and efficacy parameters were analyzed through week 24.
Safety evaluations included adverse event (AE) assessments, vital sign
measurements, electrocardiographic measurements, clinical laboratory tests,
and physical examinations. Psoriasis Area and Severity Index (PASI) response
measures the severity of psoriasis, ranging from a score of 0 (no psoriasis) to
72 (very severe).14 The proportion of patients achieving PASI responses was
assessed through week 24.Skin biopsy specimens
Two adjacent 4-mm punch biopsy specimens of lesional and nonlesional
skin were obtained at baseline and at weeks 1 and 12 after treatment with
guselkumab or placebo. One biopsy specimen from each sitewas embedded in
OCT for cryosections, and the other was immediately snap-frozen in the dry
ice/methanol slurry for RNA extraction. Both were stored at 2808C until
analysis was performed.Histology
Frozen skin tissue sections were prepared and analyzed by using
methodology described previously.6Gene expression
Skin biopsy specimens were processed and RT-PCR data were generated,
as previously described.4 For microarray, RNA was hybridized to the
GeneChip HT HG-U1331 PM Array (Affymetrix, Santa Clara, Calif).
Expression measures were obtained by using the Robust Multi-array Average
(RMA) algorithm.15 High-dose guselkumab was defined by combining sam-
ples from the 100- and 300-mg groups to increase analytic power. Comparison
between baseline and posttreatment gene expression was also analyzed for
each treatment group, excluding the 30-mg group because of smaller sample
size (n < 5), to evaluate dose-associated trend. Raw data have been deposited
in the National Center for Biotechnology Information’s Gene Expression
Omnibus (accession no. GSE51440).Serum cytokine analysis
Serum was collected from patients receiving guselkumab or placebo at
baseline and weeks 1 and 12 after treatment. IL-17A levels were measured
with Singulex (Alameda, Calif) immunoassay kits. IFN-g, IL-1b, IL-6,
TNF-a, IL-12p40, and IL-12p70 levels were measured with Meso Scale
Discovery (Rockville, Md) kits. IL-8, IL-23p19, and CCL22 levels were
measured with R&D Systems (Minneapolis, Minn) kits, and C-reactive
protein levels were measured with a Life Diagnostics (West Chester, Pa) kit.Statistical analysis
The number of patients was chosen to provide a preliminary safety and
efficacy assessment of guselkumab. No formal sample size determination was
undertaken. Only descriptive statistical methods were used to summarize the
data (no formal hypothesis testing); however, a post hoc trend analysis
using asymptotic and exact Cochran-Armitage trend tests were performed.
Demographics, baseline disease characteristics, and the proportion of patients
achieving 75% improvement in PASI scores from baseline (PASI 75) and 90%
improvement in PASI scores from baseline (PASI 90) responses at each visit
were summarized by treatment group.RESULTS
Study population
Overall, the demographics and disease characteristics of
guselkumab-treated patients were generally comparable among
treatment groups and with those of placebo-treated patients
(see Table E1 in this article’s Online Repository at www.
jacionline.org); they were typical of patients with moderate-to-
severe psoriasis and consistent with other studies of this patient
population.Neutralization of IL-23 improves clinical
manifestations of psoriasis
Patients with psoriasis (n5 24) received a single subcutaneous
injection of placebo or 10, 30, 100, or 300 mg of guselkumab.
FIG 1. Proportion of patients achieving at least a 75% improvement in Psoriasis Area and Severity Index
(PASI 75) response (A) or a PASI 90 response (B) from baseline to week 24.
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assessed through week 24. Fig 1, A, displays the proportion of
patients achieving a PASI 75 response through week 24. At
week 12, 50.0% (2/4) of patients in the 10-mg group, 60.0% (3/
5) of patients in both the 30- and 100-mg groups, and 100% of pa-
tients (5/5) in the 300-mg group achieved PASI 75 responses (Fig
1, A). A post hoc trend analysis using the asymptotic or
exact Cochran-Armitage trend test (P 5 .0197 and P 5 .0241,
respectively) showed significant linear trend in the proportion
of PASI 75 responses at week 12 with increasing dose levels.
No patients in the placebo group achieved PASI 75 responses at
any time point.
The proportion of patients achieving PASI 90 responses is
displayed in Fig 1, B. At week 12, 25.0% of patients (1/4) in the
10-mg, 40.0% (2/5) in the 30-mg, 0.0% in the 100-mg, and 80.0%
(4/5) in the 300-mg groups achieved PASI 90 responses compared
with 0.0% in the placebo group. PASI responses were generally
maintained through week 24, with the exception of the 100-mg
dose group, in which initial high levels of response were lost
over longer-term follow-up. Physician’s global assessment scores
were generally consistent with PASI responses over time (data not
shown).
Clinical improvement in psoriatic lesions after guselkumab
treatment is depicted in Fig 2. Two patients with comparable
disease severity were treated with 2 different single doses of
guselkumab, a lower dose (10 mg; Fig 2, A) and a higher dose
(300 mg; Fig 2, B), and both patients achieved PASI 90 responses
at week 12.
In general, guselkumab was well tolerated. Through week 24,
65.0% (13/20) of patients in the combined guselkumab groupsand 50% (2/4) in the placebo group experienced at least 1AE (see
Table E2 in this article’s Online Repository at www.jacionline.
org). The most common AE was infection, with 6 patients expe-
riencing a total of 9 infections. The infections were 2 events of up-
per respiratory tract infection and 1 report each of bronchitis,
folliculitis, viral gastroenteritis, herpes simplex infection, lower
respiratory tract infection, vaginal infection, and nasopharyngitis
(data not shown). Although it is not possible to draw conclusions
about the risk of infection associated with guselkumab based on
this one small study, infections are a theoretic risk for any immu-
nomodulating agent and will therefore continue to be monitored
in future guselkumab studies.
No serious infections, malignancies, major adverse cardio-
vascular events, serious hypersensitivity reactions, or deaths were
reported through week 24. This AE profile and overall compre-
hensive safety data suggest that guselkumab, when administered
as a single subcutaneous injection, was well-tolerated.Guselkumab eliminates pathologic cellular skin
infiltrates in patients with psoriasis
Serum and skin biopsy specimens were collected before
initiation of treatment (baseline) and at weeks 1 and 12 for
analysis of disease-related biomarkers and histopathology.
Changes in keratinocyte proliferation and leukocyte infiltration
were measured to evaluate the extent to which IL-23 regulates
psoriasis-specific disease features.
Immunohistochemistry was performed to determine the
cellular composition of the biopsied skin tissue. At baseline,
increases in T-cell counts (CD3), myeloid DC counts (CD11c),
FIG 2. A, Clinical response to a single dose of 10 mg of guselkumab admin-
istered at baseline. B, Clinical response to a single dose of 300 mg of gusel-
kumab administered at baseline.
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[KRT16]) were observed in lesional skin compared with values in
nonlesional skin (Fig 3). At week 1, modest improvement
was observed from baseline in epidermal thickness and in
numbers of CD31 or CD11c1 immune cells (Fig 4). At week
12, statistically significant reductions in epidermal thickness
and T-cell and inflammatory CD11c1 DC counts were observed
for each guselkumab dose group compared with baseline (P <
.05 each), with the exception of DC counts in the 10-mg group
(P5.0723, Fig 4). Langerhans cells, which are displaced in active
psoriatic lesions, resumed a normal panepidermal pattern in
guselkumab-treated biopsy specimens at week 12 (Fig 3). No
reduction was observed in epidermal thickness or T-cell density
in placebo-treated patients; however, a significant reduction
from baseline in DC counts was observed for placebo at week
12 (P 5 .0284).Guselkumab attenuates TH17 molecular biomarkers
in psoriatic skin
Skin tissue biopsy specimens were also evaluated for gene
expression by using quantitative RT-PCR andmicroarray analysis
(Fig 5). Fig 5, A, shows expression of KRT16, IFN-g, IL-17F, andlipocalin 2 (LCN2) mRNAs at baseline and week 12 from biopsy
specimens of patients receiving placebo or high-dose guselkumab
(100- and 300-mg groups combined). KRT16 expression was
significantly decreased with guselkumab treatment to levels less
than those observed in nonlesional skin. IFN-g mRNA levels
increased slightly with guselkumab treatment, as might be pre-
dicted from specific IL-23 blockade. Although not statistically
significant, there was a marked reduction in expression of IL-
17F (mean reduction, 26-fold; P 5 .057) and a modest (2-fold)
reduction in IL-17A mRNA expression after guselkumab
treatment (data not shown). The expression of LCN2, CXCL1
(Table I), and S100A7 (S100A15), which are strongly induced
by IL-17 in psoriatic lesions, was significantly decreased after
guselkumab treatment. CXCL10 (regulated by type I and type
II interferons) and IL-22 expression was reduced at week 12,
although less consistently (mean of 8- and 10-fold; P 5 .15 and
P 5 .11, respectively) than expression of IL-17–targeted genes
(data not shown). These data suggest that IL-23 regulates
expression of IL-17 and IL-17 pathway gene targets in psoriasis
lesions, with limited effect on TH1 pathway gene targets (IFN-g
producing).
Affymetrix microarrays were used to define the transcriptome
of lesional and nonlesional skin at baseline and weeks 1 and 12
after guselkumab treatment to assess the overall effect of
guselkumab on the molecular disease profile (Fig 5, B; see
Table E3 in this article’s Online Repository at www.
jacionline.org). The disease profile was defined as 1224 tran-
scripts (891 unique ENTREZ-annotated genes) with significant
modulations in gene expression when comparing lesional with
nonlesional biopsy specimens at baseline. These genes are high-
ly characteristic of the psoriasis disease profile reported
recently.4 Of the 1224 disease-profile genes described here,
1170 were normalized by 70% or greater in week-12 biopsy
specimens of psoriatic lesions treated with high-dose guselku-
mab (data not shown). Some improvement in the disease profile
was evident at week 1, but the week-12 response was much
stronger because the overall gene expression pattern is very
similar to that of nonlesional skin at baseline. Significant reduc-
tions, with a smaller magnitude of change, were observed in the
10- and 30-mg groups (data not shown). Expression of KRT6A
and KRT16 was significantly reduced by high-dose guselkumab
from baseline to week 12 (21- and 19-fold, respectively), indi-
cating a strong reduction in regenerative epidermal growth.
Similar significant downregulation (>15-fold) was observed
for S100A7A (S100A15), S100A7 (psoriasin), S100A8, and
S100A9 (see Table E3). Interestingly, expression levels of
KRT6 and KRT16, as well as levels of the S100 proteins,
were modulated to levels less than the starting values in nonle-
sional skin at baseline. Additionally, a dose-dependent reduction
in the expression of S100A proteins, KRT6A, KRT16, and
LCN2 was observed (data not shown).
Microarray analysis also detected significant modulations in
694 genes by guselkumab (see Table E3), which were not
classified as ‘‘disease-related’’ in this study. Approximately half
of these genes (310 probes), however, were identified as a part
of the psoriasis transcriptome in another recent study with a
much larger patient cohort,4 andmany of the 384 remaining genes
are related to cell growth or inflammation pathways. The effects
of high-dose guselkumab on genes involved in the IL-17 pathway,
epidermal hyperplasia, and additional immune pathways are
shown in Table I.
FIG 3. Histologic evaluation of nonlesional and lesional skin at baseline and week 12 after subcutaneous
injection of 300 mg of guselkumab. CD3, T cell; CD11c, myeloid DC; H&E, hematoxylin and eosin; KRT16,
keratin 16.
FIG 4. Evaluation of mean epidermal thickness and T-cell (CD3) and myeloid DC (CD11c) expression from
lesional skin biopsy specimens at baseline and after guselkumab or placebo treatment at weeks 1 and 12.
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FIG 5. A, Expression of KRT16, IFN-g, IL-17F, and LCN2 mRNA at baseline and week 12 in lesional and
nonlesional biopsy specimens from patients treated with high-dose (100 mg 1 300 mg) guselkumab
compared with placebo. B,Microarray expression of 1224 transcripts of nonlesional skin at baseline versus
lesional skin at baseline and at weeks 1 and 12 after guselkumab treatment.
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TABLE I. Real-time reverse transcriptase PCR
Differentially expressed genes Gene name
High-dose guselkumab
responders* Placebo-treated
Fold-change
(wk 12 vs baseline) P value
Fold-change
(wk 12 vs baseline) P value
IL-17 pathway related
S100A7A S100 calcium-binding protein A7A <21000 4.86 3 1027 21.31 .9492
IL-8 IL-8 2699.81 .0006 218.42 .4561
LCN2 Lipocalin 2 2244.37 .0001 1.24 .9426
CXCL1 C-X-C motif ligand 1 2157.06 .0015 1.6 .8859
RORC RAR-related orphan receptor C 48.05 .0173 1.41 .9208
Epidermal hyperplasia
KRT16 Keratin 16 2149.26 3.11 3 10210 1.22 .8962
STAT3 Signal transducer and activator of transcription 3 24.93 .0195 2.35 .5598
Other immune pathways
NOS2 Nitric oxide synthase 2 2145.48 .0059 21.12 .9762
MX1 Myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
217.45 .0006 2.2 .6541
GBP1 Guanylate-binding protein 1, interferon-inducible 26.42 .0139 1.07 .9677
STAT5A Signal transducer and activator of transcript 5A 19.25 .0497 23.86 .6775
MUC7 Mucin 7 157.52 .0379 21.63 .926
*Patients treated with 100 and 300 mg of guselkumab were grouped (high dose) for this analysis. Responders were defined as patients reporting at least a 50% improvement in
PASI response (PASI 50) from baseline to week 12.
FIG 6. Serum analyses of circulating IL-17A levels in guselkumab-treated
responders (PASI 50 response at week 12) at baseline and at weeks 1 and
12 compared with the placebo-treated group. P values measure the
significant difference in posttreatment compared with baseline values.
*P 5 .031 and **P 5 .0015.
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responding to guselkumab
IL-17 levels are increased in the lesional skin and blood of
patients with psoriasis3,16-18 and correlate with disease severity.19
One of the most direct pharmacodynamic measures of IL-23 inhi-
bition in serum is a reduction of downstream IL-17A levels.
IL-17A levels were analyzed at baseline and weeks 1 and 12 inguselkumab responders (guselkumab-treated patients with >_PASI
50 at week 12) compared with placebo-treated patients to explore
whether serum IL-17A levels could be used to monitor response
(Fig 6). Significant reductions from baseline in circulating
IL-17A levels were observed at week 1 (P 5 .031) and week 12
(P5 .0015) in guselkumab responders (n 5 17), and no changes
were observed in the placebo group. Although expression of
genes pertinent to the IL-17A pathway was reduced in a
dose-dependent manner, a similar dose trend was not observed
with serum IL-17A levels (data not shown).
Ten other serum proteins were analyzed for changes
after treatment with guselkumab, including inflammatory
proteins: IFN-g, IL-1b, IL-6, TNF-a, IL-12p40, IL-12p70,
IL-8, C-reactive protein, IL-23p19, and CCL22 (MDC).
CCL22 was the only analyte significantly reduced at week
12 after guselkumab treatment compared with placebo. No
significant changes were noted for the other proteins (data not
shown).DISCUSSION
The results of this study establish that selective antagonism of
IL-23 with guselkumab leads to clinical improvement in patients
with psoriasis that is associated with reductions in cellular
and molecular disease biomarkers in skin biopsy specimens.
These data should be used to refine our current model of
psoriasis pathogenesis. The current model involves not only the
IL-23/TH17 axis but also IFN-g–producing TH1/TC1 cells and
IL-22–producing TH22/TC22 cells. Activated DCs in the skin
release IL-121 and IL-23,20 which influence resident T cells to
differentiate into TH1/TC1, TH17/TC17, and TH22/TC22 cells.
3
In this model, cytokines released from distinct T-cell subsets
cause epidermal keratinocytes to increase transcription of
cytokine-specific gene products, and the psoriasis molecular
phenotype is created by the collective response of keratinocytes
to the array of cytokines produced in skin lesions. Our results
suggest that the current working model should be revised to
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cytokine are sufficient to drive most of the disease phenotype,
even if the IL-12/TH1 axis continues to be expressed in skin
lesions.
The importance of the IL-23/TH17 T-cell axis in psoriasis
pathogenesis is also suggested in recent studies with IL-17
antagonists in patients with psoriasis,6,21-23 but with the caveat
that reductions in IL-12 and IFN-g levels were also produced
by antagonizing IL-17. The central role of IL-23 in psoriasis
pathogenesis is supported by genetic links of IL-23 and IL-23R
alleles to psoriasis susceptibility.24,25 Specifically, p19 mRNA
is consistently overexpressed in psoriatic lesions,10,11 and the
IL-23 risk allele increases TH17 T-cell effector function
in vitro.26 Reports suggest that IL-23 can drive IL-17 production
by cell populations beyond traditional CD41 and CD81 T cells in
patients with psoriasis. Neutrophils, mast cells, and innate
lymphoid cells have also been implicated as additional sources
of IL-17.7 IL-23 can induce the formation of extracellular
traps, structures involved in antimicrobial activity of neutrophils
and mast cells, and these structures colocalized with IL-17 in
psoriatic skin.7 Additionally, several groups have identified
dermal gd T cells that secrete IL-17 in response to IL-23
ex vivo.27,28
Because guselkumab can antagonize the IL-23/TH17
pathway with limited effects on the IL-12/TH1 arm and results
in the collapse of major inflammatory circuits in patients with
psoriasis, this study helps confirm that the IL-23/IL-17
pathway plays a central role in the current model of psoriasis
pathogenesis. IL-17 antagonists, including ixekizumab and
secukinumab (anti–IL-17A mAbs) and brodalumab (an anti–
IL-17 receptor A mAb), are currently being studied in patients
with psoriasis.6,21-23 Based on these limited published phase 1
data, the clinical efficacy of guselkumab is generally compa-
rable with the results reported for ixekizumab22 and brodalu-
mab.23 Although inadequate data exist from phase 1 and 2
studies assessing the long-term safety of IL-23 or IL-17 antag-
onists, data for ustekinumab, which inhibits both IL-12 and
IL-23, demonstrate a favorable benefit/risk profile in patients
with moderate-to-severe psoriasis treated for up to 5 years.29
Currently, the differences between the effects of IL-17 and
IL-23 inhibition in patients are unknown. Upstream of
IL-17, inhibition of IL-23 might have more pleiotropic effects
than inhibition of IL-17. Although IL-17– or IL-17 receptor–
specific antibodies suppress IL-17 levels, specific neutraliza-
tion of IL-23 might decrease the number and activity of
pathogenic TH17 cells in the tissue. Comparative studies
would be needed to evaluate whether IL-17 or IL-23 antago-
nism would result in differences in the maintenance of efficacy
or safety.
In conclusion, this small clinical study provides evidence
of clinical response, proof-of-concept, and safety of a
single subcutaneous administration of guselkumab, an anti–
IL-23–specific mAb, in patients with moderate-to-severe psori-
asis. The range of doses of guselkumab included in this clinical
study were well-tolerated, demonstrated significant dose-
dependent clinical response, and modulated pathogenic TH17
pathways, suggesting that neutralization of IL-23 alone is a
valid therapeutic approach in patients with psoriasis. The
benefit/risk profile of guselkumab in patients with psoriasis
will be further defined in a larger study (X-PLORE,
NCT01483599).We thank Kristin Ruley Sharples, PhD, of Janssen Scientific Affairs, LLC,
and Leanne Johnson-Huang, PhD, of The Rockefeller University for their
writing and editorial support in the preparation of this article.
Clinical implications: This initial study of guselkumab for
plaque psoriasis demonstrates substantial clinical response.
Further studies are warranted to verify this effect and
characterize the safety profile.REFERENCES
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